FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Grever

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Amir Mortazavi; Gregory A Otterson; Mitch A Phelps; Lai Wei; Xin Wu; Yun Yen; Bing-Sen Zhou; Deidre Deam; Michael R Grever; Erica J Harper; William J Hicks; S Percy Ivy; Yonghua Ling; Xiyong Liu; Zhongfa Liu; Ludmila Katherine Martin; J Paul Monk; Tanios Bekaii-Saab
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Jia Ji; Amy J Johnson; Diane R Mould; Kristie A Blum; John C Byrd; Michael R Grever; Ming Poi; Amy S Ruppert; Yuan Zhao; Mitch A Phelps
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Houda Alachkar; John C Byrd; Michael A Caligiuri; Ramiro Garzon; Michael R Grever; Jason G Harb; Christopher J Hickey; A Douglas Kinghorn; David M Lucas; Joshua J Oaks; Li Pan; Danilo Perrotti; Ramasamy Santhanam; Guido Marcucci
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Grever (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Amir Mortazavi; Gregory A Otterson; Mitch A Phelps; Lai Wei; Xin Wu; Yun Yen; Bing-Sen Zhou; Deidre Deam; Michael R Grever; Erica J Harper; William J Hicks; S Percy Ivy; Yonghua Ling; Xiyong Liu; Zhongfa Liu; Ludmila Katherine Martin; J Paul Monk; Tanios Bekaii-Saab
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Investigational new drugs 2013;31(3):685-95.
2013: Jia Ji; Amy J Johnson; Diane R Mould; Kristie A Blum; John C Byrd; Michael R Grever; Ming Poi; Amy S Ruppert; Yuan Zhao; Mitch A Phelps
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(5):1269-80.
2013: Houda Alachkar; John C Byrd; Michael A Caligiuri; Ramiro Garzon; Michael R Grever; Jason G Harb; Christopher J Hickey; A Douglas Kinghorn; David M Lucas; Joshua J Oaks; Li Pan; Danilo Perrotti; Ramasamy Santhanam; Guido Marcucci
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Journal of hematology & oncology 2013;6():21.
2013: Jianhua Yu; XiaoKui Mo; Yong Peng; Qi-En Wang; Lai-Chu Wu; Zhiliang Xie; Kenneth K Chan; Ming Chiu; Youcai Deng; Michael R Grever; Shun He; Xiaoming He; Tiffany Hughes; Shujun Liu; Zhongfa Liu
Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.
PloS one 2013;8(2):e55934.
2013: Hongyan Wang; Jiang Wang; Alice Mims; Ramasamy Santhanam; U V Vijaya Saradhi; Sebastian Schwind; Miguel A Villalona-Calero; Alison Walker; Josephine Aimiuwu; William Blum; John C Byrd; Kenneth K Chan; Ping Chen; Ramiro Garzon; Michael R Grever; Rebecca B Klisovic; Zhongfa Liu; Guido Marcucci
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
The AAPS journal 2013;15(1):242-9.
2013: B F Chu; Michael R Grever; M J Karpenko; Z Liu; J Aimiuwu; Kenneth K Chan; Miguel A Villalona-Calero; Gregory A Otterson
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 2013;71(1):115-21.
2012: Samantha M Jaglowski; Jeffrey A Jones; Amy S Ruppert; Anissa Bingman; John C Byrd; Steven M Devine; Patrick Elder; Joseph M Flynn; Michael R Grever; Nyla A Heerema; Leslie A Andritsos
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.
British journal of haematology 2012;159(1):82-7.
2012: Pearlly Yan; Clara D Bloomfield; William Blum; Ralf Bundschuh; John C Byrd; Michael A Caligiuri; John Curfman; David Frankhouser; Ramiro Garzon; Susan Geyer; Michael R Grever; Samson Jacob; Rebecca B Klisovic; Klaus Metzeler; Mark Murphy; Benjamin Rodriguez; Hok-Hei Tam; Michael Trimarchi; Alison Walker; Susan P Whitman; Yue-Zhong Wu; Guido Marcucci
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
Blood 2012;120(12):2466-74.
2012: Lapo Alinari; Robert A Baiocchi; Ryan B Edwards; Michael R Grever; David Jarjoura; A Douglas Kinghorn; Amy Lehman; Rajeswaran Mani; Li Pan; Courtney J Prince; William H Towns; Xiaoli Zhang; David M Lucas
Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4600-11.
2012: Emilia Mahoney; Lisa L Smith; Amy J Wagner; Yuh-Ying Yeh; Xiaoli Zhang; Leslie Andritsos; Kristie A Blum; Joseph M Flynn; Michael R Grever; Sneha V Gupta; Metin Gurcan; Sarah Elizabeth May Herman; Amy J Johnson; Jeffrey A Jones; Hui Kong; Amy Lehman; David M Lucas; John C Byrd
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Blood 2012;120(6):1262-73.
2012: William Blum; John C Byrd; Michael A Caligiuri; Kenneth K Chan; John P Curfman; Steven M Devine; Ann-Kathrin Eisfeld; Celia Garr; Ramiro Garzon; Susan Geyer; Michael R Grever; Samson Jacob; Cheryl Kefauver; Rebecca B Klisovic; Danilo Perrotti; Ramasamy Santhanam; Sebastian Schwind; Somayeh S Tarighat; Alison Walker; Hongyan Wang; Susan Whitman; Clara D Bloomfield; Guido Marcucci
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blood 2012;119(25):6025-31.
2012: J A Woyach; K A Blum; J M Flynn; Michael R Grever; Nyla A Heerema; A J Johnson; J A Jones; A Lozanski; Gerard Lozanski; Amy S Ruppert; John C Byrd
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
Leukemia 2012;26(6):1442-4.
2012: Bhuvaneswari Ramaswamy; Lai Wei; Deidre Wilkins; Anna Wolfson; Daria Arbogast; Robert Baiocchi; Tanios Bekaii-Saab; John C Byrd; Angela Campbell; Austin Doyle; Michael R Grever; Ju-Ping Lai; Mark E Lustberg; Wenjun Ni; Mitch A Phelps; Manisha H Shah
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Investigational new drugs 2012;30(2):629-38.
2012: Deborah M Stephens; Kristie Blum; Joseph M Flynn; Michael R Grever; Jia Ji; Amy J Johnson; Jeffrey Jones; Mitch A Phelps; Amy S Ruppert; John C Byrd
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
Haematologica 2012;97(3):423-7.
2012: Jeffrey A Jones; Eric H Kraut; John C Byrd; Deidre Deam; Michael R Grever
Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
Leukemia & lymphoma 2012;53(3):490-1.
2011: Mitchell R Smith; Frederick R Appelbaum; John M Bennett; John C Byrd; Gordon Dewald; Ian W Flinn; Michael R Grever; Mohamad A Hussein; Richard A Larson; Hillard M Lazarus; Mark R Litzow; Donna Neuberg; Elisabeth Paietta; Jacob M Rowe; Martin S Tallman
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
Blood 2011;118(13):3525-7.
2011: Craig C Hofmeister; Jia Ji; Amy J Johnson; Eric H Kraut; Seungsoo Lee; Zhongfa Liu; Flavia Pichiorri; Darlene M Rozewski; Larry J Schaaf; Xiaoxia Yang; Don M Benson; John C Byrd; Kenneth K Chan; Ching-Shih Chen; Ping Chen; Sherif S Farag; Celia L Garr; Michael R Grever; Erinn M Hade; William J Hicks; Mitch A Phelps
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(25):3427-34.
2011: K A Blum; L Andritsos; J M Flynn; Michael R Grever; J Ji; A J Johnson; J A Jones; M Phelps; B Rovin; Amy S Ruppert; M Villalona-Calero; J A Woyach; John C Byrd
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Leukemia 2011;25(9):1444-51.
2011: Sneha V Gupta; Nyla A Heerema; David Jarjoura; A Douglas Kinghorn; Amy Lehman; Gerard Lozanski; John C Byrd; Kenneth K Chan; Melanie E Davis; Ryan B Edwards; Michael R Grever; Li Pan; Mitch A Phelps; Ellen J Sass; Xiaoli Zhang; David M Lucas
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.
The AAPS journal 2011;13(3):357-64.
2011: U V R Vijaya Saradhi; Jiang Wang; Ming Chiu; Joseph M Covey; Michael R Grever; Sneha V Gupta; A Douglas Kinghorn; Yonghua Ling; Zhongfa Liu; David M Lucas; Guido Marcucci; David J Newman; Mitch A Phelps; Kenneth K Chan
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.
The AAPS journal 2011;13(3):347-56.
2011: Michael R Grever
Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas.
Leukemia & lymphoma 2011;52 Suppl 2():25-8.
2011: Leslie A Andritsos; Michael R Grever
Salvage therapy for relapsed chronic lymphocytic leukemia.
Expert review of hematology 2011;4(2):199-212.
2011: Eric H Kraut; Chris A Rhoades; Yilong Zhang; Hao Cheng; Josephine Aimiumu; Ping Chen; James Lang; Donn C Young; Amit Agrawal; Janet Dancey; Kenneth K Chan; Michael R Grever
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Cancer chemotherapy and pharmacology 2011;67(3):579-86.
2011: Michael R Grever; Gerard Lozanski
Modern strategies for hairy cell leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):583-90.
2010: William Blum; Rebecca B Klisovic; Heiko Becker; Xiaoxia Yang; Darlene M Rozewski; Mitch A Phelps; Ramiro Garzon; Alison Walker; Jason C Chandler; Susan P Whitman; John Curfman; Shujun Liu; Larry J Schaaf; Jon Mickle; Cheryl Kefauver; Steven M Devine; Michael R Grever; Guido Marcucci; John C Byrd
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):4919-25.
2010: Elaine T Lam; Jessie L-S Au; Gregory A Otterson; M Guillaume Wientjes; Ling Chen; Tong Shen; Yong Wei; Xiaobai Li; Tanios Bekaii-Saab; Anthony J Murgo; Rhonda R Jensen; Michael R Grever; Miguel A Villalona-Calero
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Cancer chemotherapy and pharmacology 2010;66(6):1019-29.
2010: William Blum; Mitch A Phelps; Rebecca B Klisovic; Darlene M Rozewski; Wenjun Ni; Katie A Albanese; Brad H Rovin; Cheryl Kefauver; Steven M Devine; David M Lucas; Amy Johnson; Larry J Schaaf; John C Byrd; Guido Marcucci; Michael R Grever
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
Haematologica 2010;95(7):1098-105.
2010: Kristie A Blum; Zhongfa Liu; David M Lucas; Ping Chen; Zhiliang Xie; Robert Baiocchi; Donald M Benson; Steven M Devine; Jeffrey Jones; Leslie Andritsos; Joseph Flynn; Christoph Plass; Guido Marcucci; Kenneth K Chan; Michael R Grever; John C Byrd
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
British journal of haematology 2010;150(2):189-95.
2010: David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Potential of plant-derived natural products in the treatment of leukemia and lymphoma.
Current drug targets 2010;11(7):812-22.
2010: Neil E Kay; Wenting Wu; Brian Kabat; Betsy LaPlant; Thomas S Lin; John C Byrd; Diane F Jelinek; Michael R Grever; Clive S Zent; Timothy G Call; Tait D Shanafelt
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
Cancer 2010;116(9):2180-7.
2010: Bhuvaneswari Ramaswamy; Tanios Bekaii-Saab; Larry J Schaaf; Gregory B Lesinski; David M Lucas; Donn C Young; Amy S Ruppert; John C Byrd; Kristy Culler; Diedre Wilkins; John J Wright; Michael R Grever; Charles L Shapiro
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2010;66(1):151-8.
2010: Janet E Dancey; Kevin K Dobbin; Susan Groshen; J Milburn Jessup; Andrew H Hruszkewycz; Maria Koehler; Ralph Parchment; Mark J Ratain; Lalitha K Shankar; Walter M Stadler; Lawrence True; Amy Gravell; Michael R Grever
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1745-55.
2010: Thomas S Lin; Kristie A Blum; Diane Beth Fischer; Sarah M Mitchell; Amy S Ruppert; Pierluigi Porcu; Eric H Kraut; Robert A Baiocchi; Mollie E Moran; Amy J Johnson; Larry J Schaaf; Michael R Grever; John C Byrd
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):418-23.
2010: Michael R Grever
How I treat hairy cell leukemia.
Blood 2010;115(1):21-8.
2010: Wenjun Ni; Jia Ji; Zunyan Dai; Audrey Papp; Amy J Johnson; Sunjoo Ahn; Katherine L Farley; Thomas S Lin; James T Dalton; Xiaobai Li; David Jarjoura; John C Byrd; Wolfgang Sadee; Michael R Grever; Mitch A Phelps
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
PloS one 2010;5(11):e13792.
2010: David M Lucas; Lapo Alinari; Derek A West; Melanie E Davis; Ryan B Edwards; Amy J Johnson; Kristie A Blum; Craig C Hofmeister; Michael A Freitas; Mark R Parthun; Dasheng Wang; Amy Lehman; Xiaoli Zhang; David Jarjoura; Samuel K Kulp; Carlo M Croce; Michael R Grever; Ching-Shih Chen; Robert A Baiocchi; John C Byrd
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
PloS one 2010;5(6):e10941.
2009: Thomas S Lin; Amy S Ruppert; Amy J Johnson; Beth Fischer; Nyla A Heerema; Leslie A Andritsos; Kristie A Blum; Joseph M Flynn; Jeffrey A Jones; Weihong Hu; Mollie E Moran; Sarah M Mitchell; Lisa L Smith; Amy J Wagner; Chelsey A Raymond; Larry J Schaaf; Mitch A Phelps; Miguel A Villalona-Calero; Michael R Grever; John C Byrd
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):6012-8.
2009: Gregory C Kane; Michael R Grever; John I Kennedy; Mary Ann Kuzma; Alan R Saltzman; Peter H Wiernik; Nicole V Baptista
The anticipated physician shortage: meeting the nation's need for physician services.
The American journal of medicine 2009;122(12):1156-62.
2009: Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn M Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
Leukemia & lymphoma 2009;50(12):1958-63.
2009: Tanios S Bekaii-Saab; Julie M Roda; Kristan D Guenterberg; Bhuvanaswari Ramaswamy; Donn C Young; Amy K Ferketich; Tammy A Lamb; Michael R Grever; Charles L Shapiro; William E Carson
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
Molecular cancer therapeutics 2009;8(11):2983-91.
2009: Pravin T P Kaumaya; Kevin Chu Foy; Joan Garrett; Sharad V Rawale; Daniele Vicari; Jennifer M Thurmond; Tammy Lamb; Aruna Mani; Yahaira Kane; Catherine R Balint; Donald Chalupa; Gregory A Otterson; Charles L Shapiro; Jeffrey M Fowler; Michael R Grever; Tanios S Bekaii-Saab; William E Carson
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5270-7.
2009: Sherif S Farag; Shuhong Zhang; Buffy S Jansak; Xiaojing Wang; Eric Kraut; Kenneth Chan; Janet E Dancey; Michael R Grever
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
Leukemia research 2009;33(11):1475-80.
2009: Michael R Grever; Pier Luigi Zinzani
Long-term follow-up studies in hairy cell leukemia.
Leukemia & lymphoma 2009;50 Suppl 1():23-6.
2009: Michael R Grever
Dedication to the clinical investigators for their work with hairy cell leukemia.
Leukemia & lymphoma 2009;50 Suppl 1():1.
2009: Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla A Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O Neil; Ruey-Min Lee; Mark M Zalupski; Janet Dancey; Helen Chen; Michael R Grever; Charis Eng; Miguel A Villalona-Calero
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5895-901.
2009: Tait D Shanafelt; John C Byrd; Betsy LaPLant; Clive S Zent; Tim Call; Charla Secreto; Michael R Grever; Thomas S Lin; Neil E Kay
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
British journal of haematology 2009;146(6):660-4.
2009: Ping Chen; Zhongfa Liu; Shujun Liu; Zhiliang Xie; Josephine Aimiuwu; Jiuxia Pang; Rebecca B Klisovic; William Blum; Michael R Grever; Guido Marcucci; Kenneth K Chan
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
Pharmaceutical research 2009;26(6):1504-15.
2009: David M Lucas; Ryan B Edwards; Gerard Lozanski; Derek A West; Jungook D Shin; Melissa A Vargo; Melanie E Davis; Darlene M Rozewski; Amy J Johnson; Bao-Ning Su; Virginia M Goettl; Nyla A Heerema; Thomas S Lin; Amy Lehman; Xiaoli Zhang; David Jarjoura; David Newman; John C Byrd; A Douglas Kinghorn; Michael R Grever
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
Blood 2009;113(19):4656-66.
2009: Mitch A Phelps; Thomas S Lin; Amy J Johnson; Eunju Hurh; Darlene M Rozewski; Katherine L Farley; Di Wu; Kristie A Blum; Beth Fischer; Sarah M Mitchell; Mollie E Moran; Michelle Brooker-McEldowney; Nyla A Heerema; David Jarjoura; Larry J Schaaf; John C Byrd; Michael R Grever; James T Dalton
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Blood 2009;113(12):2637-45.
2009: Xiaodan Su; David M Lucas; Liwen Zhang; Hua Xu; Vlad Zabrouskov; Melanie E Davis; Amy R Knapp; Donn C Young; Philip R O Payne; Mark R Parthun; Guido Marcucci; Michael R Grever; John C Byrd; Michael A Freitas
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
Proteomics 2009;9(5):1197-206.
2009: Farrukh T Awan; Neil E Kay; Melanie E Davis; Wenting Wu; Susan M Geyer; Nelson Leung; Diane F Jelinek; Renee C Tschumper; Charla R Secreto; Thomas S Lin; Michael R Grever; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nyla A Heerema; Gerard Lozanski; John C Byrd; David M Lucas
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
Blood 2009;113(3):535-7.
2009: Xiaojuan Yang; Xiaobin Zhao; Mitch A Phelps; Longzhu Piao; Darlene M Rozewski; Qing Liu; L James Lee; Guido Marcucci; Michael R Grever; John C Byrd; James T Dalton; Robert J Lee
A novel liposomal formulation of flavopiridol.
International journal of pharmaceutics 2009;365(1-2):170-4.
2009: Beth A Christian; Michael R Grever; John C Byrd; Thomas S Lin
Flavopiridol in chronic lymphocytic leukemia: a concise review.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S179-85.
2008: Miguel A Villalona-Calero; Gregory A Otterson; M Guillaume Wientjes; F Weber; Tanios Bekaii-Saab; Donn Young; Anthony J Murgo; Rhonda Jensen; Teng-Kuang Yeh; Y Wei; Y Zhang; Charis Eng; Michael R Grever; Jessie L-S Au
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(11):1903-9.
2008: Qing Liu; Katherine L Farley; Amy J Johnson; Natarajan Muthusamy; Craig C Hofmeister; Kristie A Blum; Larry J Schaaf; Michael R Grever; John C Byrd; James T Dalton; Mitch A Phelps
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Therapeutic drug monitoring 2008;30(5):620-7.
2008: Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti Rai; Thomas Kipps
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Blood 2008;112(5):1923-30.
2008: Jeffrey S Johnston; Mitch A Phelps; Kristie A Blum; William Blum; Michael R Grever; Katherine L Farley; James T Dalton
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;871(1):15-21.
2008: Rebecca B Klisovic; William Blum; Xiaohui Wei; Shujun Liu; Zhongfa Liu; Zhiliang Xie; Tamara Vukosavljevic; Cheryl Kefauver; Lenguyen Huynh; Jiuxia Pang; James A Zwiebel; Steven M Devine; John C Byrd; Michael R Grever; Kenneth Chan; Guido Marcucci
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3889-95.
2008: Tanios S Bekaii-Saab; Jing Liu; Kenneth K Chan; Stanley P Balcerzak; Percy S Ivy; Michael R Grever; Eric H Kraut
A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3434-40.
2008: Mitch A Phelps; Darlene M Rozewski; Jeffrey S Johnston; Katherine L Farley; Katie A Albanese; John C Byrd; Thomas S Lin; Michael R Grever; James T Dalton
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;868(1-2):110-5.
2008: Syed-Rehan A Hussain; David M Lucas; Amy J Johnson; Thomas S Lin; Alan P Bakaletz; Vinh X Dang; Serge Viatchenko-Karpinski; Amy S Ruppert; John C Byrd; Periannan Kuppusamy; Elliott D Crouser; Michael R Grever
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
Blood 2008;111(6):3190-9.
2007: Kristie A Blum; Donn Young; Sarah Broering; Margaret S Lucas; Beth Fischer; Thomas S Lin; Michael R Grever; John C Byrd
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5624-9.
2007: Amy J Johnson; Amy J Wagner; Carolyn M Cheney; Lisa L Smith; David M Lucas; Sara K Guster; Michael R Grever; Thomas S Lin; John C Byrd
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
British journal of haematology 2007;139(5):837-44.
2007: Rebekah L Browning; Susan M Geyer; Amy J Johnson; Diane F Jelinek; Renee C Tschumper; Timothy G Call; Tait D Shanafelt; Clive S Zent; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Michael R Grever; Neil E Kay; John C Byrd; David M Lucas
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
Leukemia research 2007;31(12):1737-40.
2007: Beth A Christian; Michael R Grever; John C Byrd; Thomas S Lin
Flavopiridol in the treatment of chronic lymphocytic leukemia.
Current opinion in oncology 2007;19(6):573-8.
2007: Neil E Kay; Tait D Shanafelt; John C Byrd; Michael R Grever
Community-based phase II trial of PCR for CLL/SLL patients.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):713-4; author reply 715-7.
2007: Michael R Grever; David M Lucas; Amy J Johnson; John C Byrd
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
Best practice & research. Clinical haematology 2007;20(3):545-56.
2007: William Blum; Rebecca B Klisovic; Björn Hackanson; Zhongfa Liu; Shujun Liu; Hollie Devine; Tamara Vukosavljevic; Lenguyen Huynh; Gerard Lozanski; Cheryl Kefauver; Christoph Plass; Steven M Devine; Nyla A Heerema; Anthony J Murgo; Kenneth K Chan; Michael R Grever; John C Byrd; Guido Marcucci
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3884-91.
2007: Sharmistha Pal; Robert A Baiocchi; John C Byrd; Michael R Grever; Samson T Jacob; Saïd Sif
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
The EMBO journal 2007;26(15):3558-69.
2007: Naeem A Ali; James O'Brien; William Blum; John C Byrd; Rebecca B Klisovic; Guido Marcucci; Gary Phillips; Clay B Marsh; Stanley Lemeshow; Michael R Grever
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
Cancer 2007;110(1):96-102.
2007: Tasneem Motiwala; Sarmila Majumder; Huban Kutay; David Spencer Smith; Donna Neuberg; David M Lucas; John C Byrd; Michael R Grever; Samson T Jacob
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3174-81.
2007: Aparna Raval; Stephan M Tanner; John C Byrd; Elizabeth B Angerman; James D Perko; shih-shih chen; Björn Hackanson; Michael R Grever; David M Lucas; Jennifer J Matkovic; Thomas S Lin; Thomas Kipps; Fiona Murray; Dennis D Weisenburger; Warren G Sanger; Jane Lynch; Patrice Watson; Mary Jansen; Yuko Yoshinaga; Richard Rosenquist; Pieter J de Jong; Penny Coggill; Stephan Beck; Henry Lynch; Albert de La Chapelle; Christoph Plass
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.
Cell 2007;129(5):879-90.
2007: Tait D Shanafelt; Thomas Lin; Susan M Geyer; Clive S Zent; Nelson Leung; Brian Kabat; Deborah Bowen; Michael R Grever; John C Byrd; Neil E Kay
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
Cancer 2007;109(11):2291-8.
2007: Hao Cheng; Zhongfa Liu; William Blum; John C Byrd; Rebecca B Klisovic; Michael R Grever; Guido Marcucci; Kenneth K Chan
Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;850(1-2):206-12.
2007: Syed-Rehan A Hussain; Carolyn M Cheney; Amy J Johnson; Thomas S Lin; Michael R Grever; Michael A Caligiuri; David M Lucas; John C Byrd
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2144-50.
2007: Ian W Flinn; Donna Neuberg; Michael R Grever; Gordon W Dewald; john bennett; Elisabeth Paietta; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):793-8.
2007: Michael R Grever; David M Lucas; Gordon W Dewald; Donna Neuberg; John C Reed; Shinichi Kitada; Ian W Flinn; Martin S Tallman; Frederick R Appelbaum; Richard A Larson; Elisabeth Paietta; Diane F Jelinek; John G Gribben; John C Byrd
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):799-804.
2007: Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee C Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Blood 2007;109(2):405-11.
2007: John C Byrd; Thomas S Lin; James T Dalton; Di Wu; Mitch A Phelps; Beth Fischer; Mollie Moran; Kristie A Blum; Brad H Rovin; Michelle Brooker-McEldowney; Sarah Broering; Larry J Schaaf; Amy J Johnson; David M Lucas; Nyla A Heerema; Gerard Lozanski; Donn C Young; Jose-Ramon Suarez; A Dimitrios Colevas; Michael R Grever
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Blood 2007;109(2):399-404.
2006: Michael R Grever
Pentostatin: impact on outcome in hairy cell leukemia.
Hematology/oncology clinics of North America 2006;20(5):1099-108.
2006: Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
Blood 2006;108(4):1334-8.
2006: Manisha H Shah; Philip Binkley; Kenneth Chan; Jim Xiao; Daria Arbogast; Minden Collamore; Yasser Farra; Donn Young; Michael R Grever
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):3997-4003.
2006: Steven D Gore; Stephen B Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael A Carducci; Michael R Grever; Oliver Galm; Tianna Dauses; Judith E Karp; MICHELLE RUDEK-RENAUT; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George J Dover; Abbie Mays; James Zwiebel; Anthony J Murgo; Li-Jun Weng; James G Herman
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer research 2006;66(12):6361-9.
2006: Danny Chen; Sae Heum Song; M Guillaume Wientjes; Teng-Kuang Yeh; Liang Zhao; Miguel A Villalona-Calero; Gregory A Otterson; Rhonda Jensen; Michael R Grever; Anthony J Murgo; Jessie L-S Au
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Pharmaceutical research 2006;23(6):1265-74.
2006: Carl R Willis; Amy Goodrich; Kathy Park; Jamie K Waselenko; Margaret Lucas; Amy Reese; Louis F Diehl; Michael R Grever; John C Byrd; Ian W Flinn
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Annals of hematology 2006;85(5):301-7.
2006: John C Byrd; Thomas S Lin; Michael R Grever
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
Seminars in oncology 2006;33(2):210-9.
2006: John C Byrd; John G Gribben; Bercedis L Peterson; Michael R Grever; Gerard Lozanski; David M Lucas; Ben Lampson; Richard A Larson; Michael A Caligiuri; Nyla A Heerema
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):437-43.
2006: Zhongfa Liu; Guido Marcucci; John C Byrd; Michael R Grever; Jim Xiao; Kenneth K Chan
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.
Rapid communications in mass spectrometry : RCM 2006;20(7):1117-26.
2005: Yvette L Kasamon; Ian W Flinn; Michael R Grever; Louis F Diehl; Elizabeth Garrett-Mayer; Steven Goodman; Margaret S Lucas; John C Byrd
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8413-7.
2005: Ian W Flinn; John C Byrd; Nancy Bartlett; Thomas Kipps; John Gribben; Deborah Thomas; Richard A Larson; Kanti Rai; Rosemary Petric; Jose Ramon-Suerez; Janice Gabrilove; Michael R Grever
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
Leukemia research 2005;29(11):1253-7.
2005: Thomas S Lin; Ian W Flinn; Margaret S Lucas; Pierluigi Porcu; J Sickler; M E Moran; David M Lucas; Nyla A Heerema; Michael R Grever; John C Byrd
Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Leukemia 2005;19(7):1207-10.
2005: Jim J Xiao; Ying Huang; Zunyan Dai; Wolfgang Sadée; Jiyun Chen; Shujun Liu; Guido Marcucci; John Byrd; Joseph M Covey; John Wright; Michael R Grever; Kenneth K Chan
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
The Journal of pharmacology and experimental therapeutics 2005;314(1):467-75.
2005: Thomas S Lin; Michael R Grever; John C Byrd
Changing the way we think about chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4009-12.
2005: Aparna Raval; David M Lucas; Jennifer J Matkovic; Kristi L Bennett; Sandya Liyanarachchi; Donn C Young; Laura Rassenti; Thomas Kipps; Michael R Grever; John C Byrd; Christoph Plass
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3877-85.
2005: John C Byrd; Bercedis L Peterson; Janice Gabrilove; Olatoyosi Odenike; Michael R Grever; Kanti Rai; Richard A Larson
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4176-81.
2005: Steven D Gore; B Douglas Smith; Ivana Gojo; Michael R Grever; Scott H Kaufmann; Louis Letendre; Debra G B Leonard; Guido Marcucci; Carole B Miller; Lawrence Morris; Steven Piantadosi; Thomas Prior; Wendy Stock; Judith E Karp
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
American journal of hematology 2005;79(2):119-27.
2005: Guido Marcucci; Wendy Stock; Guowei Dai; Rebecca B Klisovic; Shujun Liu; Marko I Klisovic; William Blum; Cheryl Kefauver; Dorie A Sher; Margaret Green; Mollie Moran; Kati Maharry; steven novick; Clara D Bloomfield; James A Zwiebel; Richard A Larson; Michael R Grever; Kenneth K Chan; John C Byrd
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3404-11.
2005: Ping-Hui Tseng; Ho-Pi Lin; Jiuxiang Zhu; Kuen-Feng Chen; Erinn M Hade; Donn C Young; John C Byrd; Michael R Grever; Kara Johnson; Brian J Druker; Ching-Shih Chen
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Blood 2005;105(10):4021-7.
2005: F. JAVIER BOLANOS MEADE; David A Jacobsohn; Jeffrey Margolis; Adam Ogden; M Guillaume Wientjes; John C Byrd; David M Lucas; Viki Anders; Michele Phelps; Michael R Grever; Georgia B Vogelsang
Pentostatin in steroid-refractory acute graft-versus-host disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2661-8.
2005: Guowei Dai; Kenneth K Chan; Shujun Liu; Dale Hoyt; Susan P Whitman; Marko I Klisovic; Tiansheng Shen; Michael A Caligiuri; John Byrd; Michael R Grever; Guido Marcucci
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2998-3008.
2005: Amy J Johnson; Lisa L Smith; Jiuxiang Zhu; Nyla A Heerema; Sara Jefferson; Andrew P Mone; Michael R Grever; Ching-Shih Chen; John C Byrd
A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
Blood 2005;105(6):2504-9.
2005: John C Byrd; Guido Marcucci; Mark R Parthun; Jim J Xiao; Rebecca B Klisovic; Mollie Moran; Thomas S Lin; Shujun Liu; Amy R Sklenar; Melanie E Davis; David M Lucas; Beth Fischer; Roshini Shank; Sooraj L Tejaswi; Philip Binkley; John Wright; Kenneth K Chan; Michael R Grever
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Blood 2005;105(3):959-67.
2004: Sameek Roychowdhury; Robert A Baiocchi; Srinivas Vourganti; Darshna Bhatt; Bradley W Blaser; Aharon G Freud; Jason Chou; Chang-Shi Chen; Jim J Xiao; Mark R Parthun; Kenneth K Chan; Charles F Eisenbeis; Amy K Ferketich; Michael R Grever; Ching-Shih Chen; Michael A Caligiuri
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Journal of the National Cancer Institute 2004;96(19):1447-57.
2004: Manisha H Shah; Donn Young; Hedy L Kindler; Iain Webb; Barbara Kleiber; John Wright; Michael R Grever
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6111-8.
2004: Charles F Eisenbeis; Andrew Grainger; Beth Fischer; Robert A Baiocchi; Lester Carrodeguas; Sameek Roychowdhury; Lei Chen; Amy L Banks; Thomas Davis; Donn Young; Nicole Kelbick; Julie Stephens; John C Byrd; Michael R Grever; Michael A Caligiuri; Pierluigi Porcu
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6101-10.
2004: Thomas S Lin; Mollie Moran; Margaret Lucas; Sharon Waymer; Sara Jefferson; Diane B Fischer; Michael R Grever; John C Byrd
Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
Hematology/oncology clinics of North America 2004;18(4):895-913, ix-x.
2004: David M Lucas; Melanie E Davis; Mark R Parthun; Andrew P Mone; Shinichi Kitada; K D Cunningham; E L Flax; Joseph Wickham; John C Reed; John C Byrd; Michael R Grever
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
Leukemia 2004;18(7):1207-14.
2004: Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Blood 2004;103(9):3278-81.
2004: Guido Marcucci; Wendy Stock; Guowei Dai; Marko I Klisovic; Kati Maharry; Tiansheng Shen; Shujun Liu; Dorie A Sher; David Lucas; A Zwiebel; Richard A Larson; Michael A Caligiuri; Clara D Bloomfield; Kenneth K Chan; Michael R Grever; John C Byrd
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Annals of hematology 2004;83 Suppl 1():S93-4.
2003: Steven Z Pavletic; R Gregory Bociek; James M Foran; Ronald J Rubocki; Charles A Kuszynski; James L Wisecarver; Lori Hatcher; David M Lucas; John C Byrd; Michael R Grever; Shantaram S Joshi; Penny Hardiman; Lynette M Smith; Timothy R McGuire; Philip J Bierman; Julie M Vose; James O Armitage; James Edward Talmadge
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.
Transplantation 2003;76(5):877-81.
2003: Miguel A Villalona-Calero; M Guillaume Wientjes; Gregory A Otterson; Steven Kanter; Donn Young; Anthony J Murgo; Beth Fischer; Carrie DeHoff; Danny Chen; Teng-Kuang Yeh; SaeHeum Song; Michael R Grever; Jessie L-S Au
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3303-11.
2003: Michael R Grever
New drugs in acute myeloid leukemia.
Clinical advances in hematology & oncology : H&O 2003;1(8):456-9.
2003: Jennifer L Aron; Mark R Parthun; Guido Marcucci; Shinichi Kitada; Andrew P Mone; Melanie E Davis; Tiansheng Shen; Timothy Murphy; Joseph Wickham; Chris Kanakry; David M Lucas; John C Reed; Michael R Grever; John C Byrd
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Blood 2003;102(2):652-8.
2003: John C Byrd; David M Lucas; Andrew P Mone; Joshua B Kitner; Joseph J Drabick; Michael R Grever
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
Blood 2003;101(11):4547-50.
2003: Michael R Grever; Charles A Doan; Eric H Kraut
Pentostatin in the treatment of hairy-cell leukemia.
Best practice & research. Clinical haematology 2003;16(1):91-9.
2003: Marko I Klisovic; Eman Maghraby; Mark R Parthun; Martin Guimond; Amy R Sklenar; Susan P Whitman; Kenneth K Chan; T Murphy; J Anon; Kellie J Archer; Laura J Rush; Christoph Plass; Michael R Grever; John C Byrd; Guido Marcucci
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Leukemia 2003;17(2):350-8.
2003: Guido Marcucci; John C Byrd; Guowei Dai; Marko I Klisovic; Peter J Kourlas; Donn C Young; Spero R Cataland; Diane B Fisher; David Lucas; Kenneth K Chan; Pierluigi Porcu; Zhong-Pin Lin; Sherif F Farag; Stanley R Frankel; James A Zwiebel; Eric H Kraut; Stanley P Balcerzak; Clara D Bloomfield; Michael R Grever; Michael A Caligiuri
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Blood 2003;101(2):425-32.
2003: Jim J Xiao; John Byrd; Guido Marcucci; Michael R Grever; Kenneth K Chan
Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood.
Rapid communications in mass spectrometry : RCM 2003;17(8):757-66.
2002: Jing Liu; Eric H Kraut; Stanley P Balcerzak; Michael R Grever; Steven M D'Ambrosio; Kenneth K Chan
Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Cancer chemotherapy and pharmacology 2002;50(6):445-53.
2002: Jing Liu; Eric H Kraut; Jonathan Bender; Rebecca Brooks; Stanley P Balcerzak; Michael R Grever; Harriet Stanley; Steven M D'Ambrosio; Ruth Gibson-D'Ambrosio; Kenneth K Chan
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Cancer chemotherapy and pharmacology 2002;49(5):367-74.
2002: Steven D Gore; Li-Jun Weng; William D Figg; Suoping Zhai; Ross C Donehower; George J Dover; Michael R Grever; Constance A Griffin; Louise B. Grochow; Anita E Hawkins; Kathleen Burks; Yelena Zabelena; Carole B Miller
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):963-70.
2001: Jamie K Waselenko; CA Shinn; Carl R Willis; Ian W Flinn; Michael R Grever; John C Byrd
Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells.
Leukemia & lymphoma 2001;42(5):1049-53.
2001: Steven D Gore; Li-Jun Weng; Suoping Zhai; William D Figg; Ross C Donehower; George J Dover; Michael R Grever; Constance A Griffin; Louise B. Grochow; Eric K Rowinsky; Y Zabalena; Anita L Hawkins; Kathleen Burks; Carole B Miller
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2330-9.
2001: John C Byrd; CA Shinn; Carl R Willis; Ian W Flinn; T Lehman; Edward A Sausville; D Lucas; Michael R Grever
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Experimental hematology 2001;29(6):703-8.
2001: Jamie K Waselenko; Michael R Grever; CA Shinn; Ian W Flinn; John C Byrd
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.
Leukemia research 2001;25(6):435-40.
2001: John C Byrd; T Murphy; R S Howard; Margaret S Lucas; Amy Goodrich; Keunchil Park; M Pearson; Jamie K Waselenko; G Ling; Michael R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; Ian W Flinn
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2153-64.
2000: Ian W Flinn; Kenneth J Kopecky; M K Foucar; D Head; John M Bennett; R Hutchison; W Corbett; Peter A Cassileth; Thomas M Habermann; H Golomb; Kanti Rai; E Eisenhauer; F Appelbaum; B Cheson; Michael R Grever
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.
Blood 2000;96(9):2981-6.
2000: John C Byrd; Jamie K Waselenko; M Keating; Kanti Rai; Michael R Grever
Novel therapies for chronic lymphocytic leukemia in the 21st century.
Seminars in oncology 2000;27(5):587-97.
2000: Ian W Flinn; John C Byrd; C Morrison; J Jamison; Louis F Diehl; T Murphy; Steven Piantadosi; EJ Seifter; Richard F Ambinder; Georgia B Vogelsang; Michael R Grever
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
Blood 2000;96(1):71-5.
2000: Jamie K Waselenko; Michael R Grever; M Beer; M A Lucas; John C Byrd
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Seminars in oncology 2000;27(2 Suppl 5):44-51.
2000: John C Byrd; Michael R Grever; Jamie K Waselenko; Carl R Willis; Keunchil Park; Amy Goodrich; M A Lucas; CA Shinn; Ian W Flinn
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
Seminars in oncology 2000;27(2 Suppl 5):37-40.
2000: Jeffrey Margolis; Michael R Grever
Pentostatin (Nipent): a review of potential toxicity and its management.
Seminars in oncology 2000;27(2 Suppl 5):9-14.
1999: Chatchada Karanes; Kenneth J Kopecky; David R Head; Michael R Grever; HE Hynes; Eric H Kraut; R H Vial; A Lichtin; S Nand; W E Samlowski; Frederick R Appelbaum
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Leukemia research 1999;23(9):787-94.
1999: John C Byrd; CA Shinn; Rajani Ravi; Carl R Willis; Jamie K Waselenko; Ian W Flinn; Nancy A Dawson; Michael R Grever
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.
Blood 1999;94(4):1401-8.
1999: CP Leith; Kenneth J Kopecky; I-Ming Chen; L Eijdems; Marilyn L Slovak; T S McConnell; David R Head; J Weick; Michael R Grever; Frederick R Appelbaum; Cheryl L Willman
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
Blood 1999;94(3):1086-99.
1999: Martin S Tallman; David Hakimian; Kenneth J Kopecky; S Wheaton; ER Wollins; K Foucar; Peter A Cassileth; Thomas M Habermann; Michael R Grever; Jacob M Rowe; LoAnn C Peterson
Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1665-70.
1999: H Carlos Nousari; Robert A Brodsky; Richard J Jones; Michael R Grever; Grant J Anhalt
Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease.
Journal of the American Academy of Dermatology 1999;40(5 Pt 1):750-4.
1998: John C Byrd; CA Shinn; Jamie K Waselenko; Ephraim J Fuchs; T A Lehman; P L Nguyen; Ian W Flinn; Louis F Diehl; Edward A Sausville; Michael R Grever
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Blood 1998;92(10):3804-16.
1998: Steven D Gore; Eric K Rowinsky; Carole B Miller; Constance A Griffin; Tian Ling Chen; Michael J Borowitz; Ross C Donehower; Kathleen Burks; Deborah K Armstrong; PJ Burke; Michael R Grever; Scott H Kaufmann
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2677-89.
1998: Robert Z Orlowski; J R Eswara; Anne Lafond-Walker; Michael R Grever; M Orlowski; Chi Dang
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
Cancer research 1998;58(19):4342-8.
1998: John C Byrd; Kanti Rai; Edward A Sausville; Michael R Grever
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
Seminars in oncology 1998;25(1):65-74.
1998: John C Byrd; Ian W Flinn; Michael R Grever
Introduction: chronic lymphocytic leukemia.
Seminars in oncology 1998;25(1):4-5.
1996: J K Weick; Kenneth J Kopecky; Frederick R Appelbaum; D R Head; L L Kingsbury; Stanley P Balcerzak; J N Bickers; HE Hynes; Jeanna Welborn; S R Simon; Michael R Grever
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Blood 1996;88(8):2841-51.
1996: Bruce D Cheson; J M Bennett; Michael R Grever; N Kay; M J Keating; S O'Brien; Kanti Rai
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Blood 1996;87(12):4990-7.
1996: Edward A Sausville; KL Duncan; Adrian M Senderowicz; J Plowman; Paul A Randazzo; Richard A Kahn; L Malspeis; Michael R Grever
Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A.
The cancer journal from Scientific American 1996;2(1):52-8.
1996: Ian W Flinn; Michael R Grever
Chronic lymphocytic leukemia.
Cancer treatment reviews 1996;22(1):1-13.
1995: Melinda G Hollingshead; J Roberson; W Decker; Robert W Buckheit; C Elder; L Malspeis; J Mayo; Michael R Grever
In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.
Antiviral research 1995;28(3):265-79.
1995: Angelika Burger; G Kaur; M C Alley; J G Supko; L Malspeis; Michael R Grever; Edward A Sausville
Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.
Cancer research 1995;55(13):2794-9.
1995: M Alvarez; KD Paull; Anne Monks; C Hose; J S Lee; J Weinstein; Michael R Grever; Susan Bates; Tito Fojo
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
The Journal of clinical investigation 1995;95(5):2205-14.
1995: C L Bigelow; K Kopecky; J C Files; D Head; D A Lipschitz; Michael R Grever; F R Appelbaum
Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
American journal of hematology 1995;48(4):228-32.
1995: Michael R Grever; K Kopecky; M K Foucar; D Head; J M Bennett; R E Hutchison; W E Corbett; Peter A Cassileth; T Habermann; H Golomb
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(4):974-82.
1995: J Plowman; D J Dykes; V L Narayanan; B J Abbott; H Saito; T Hirata; Michael R Grever
Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice.
Cancer research 1995;55(4):862-7.
1995: Adrian M Senderowicz; G Kaur; Eduardo Sainz; C Laing; W D Inman; J Rodríguez; P Crews; L Malspeis; Michael R Grever; Edward A Sausville
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.
Journal of the National Cancer Institute 1995;87(1):46-51.
1995: J G Supko; R L Hickman; Michael R Grever; L Malspeis
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
Cancer chemotherapy and pharmacology 1995;36(4):305-15.
1994: J J Casciari; Melinda G Hollingshead; M C Alley; J G Mayo; L Malspeis; S Miyauchi; Michael R Grever; John N Weinstein
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.
Journal of the National Cancer Institute 1994;86(24):1846-52.
1994: Eric H Kraut; Michael R Grever; B A Bouroncle
Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin.
Blood 1994;84(12):4061-3.
1994: J S Lee; KD Paull; M Alvarez; C Hose; Anne Monks; Michael R Grever; Antonio Tito Fojo; Susan E Bates
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Molecular pharmacology 1994;46(4):627-38.
1994: J Plowman; William R Waud; A D Koutsoukos; L V Rubinstein; T D Moore; Michael R Grever
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Cancer research 1994;54(14):3793-9.
1994: P S Steeg; M C Alley; Michael R Grever
An added dimension: will three-dimensional cultures improve our understanding of drug resistance?
Journal of the National Cancer Institute 1994;86(13):953-5.
1994: A A Scott; D R Head; Kenneth J Kopecky; Frederick R Appelbaum; K S Theil; Michael R Grever; I-Ming Chen; M H Whittaker; B B Griffith; Jonathan D Licht
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Blood 1994;84(1):244-55.
1994: Michael R Grever; J Benedetti; S P Balcerzak; Sarah A Taylor; T P Miller; S R Dakhil
A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.
Investigational new drugs 1994;12(3):259-61.
1993: Gordon M Cragg; S A Schepartz; M Suffness; Michael R Grever
The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents.
Journal of natural products 1993;56(10):1657-68.
1993: Ellen G Feigal; M Christian; Bruce D Cheson; Michael R Grever; M A Friedman
New chemotherapeutic agents in non-small-cell lung cancer.
Seminars in oncology 1993;20(2):185-201.
1993: L Elias; D Stock-Novack; D R Head; Michael R Grever; J K Weick; Robert A Chapman; J E Godwin; E N Metz; F R Appelbaum
A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.
Leukemia 1993;7(3):361-5.
1992: Michael R Grever; S A Schepartz; B A Chabner
The National Cancer Institute: cancer drug discovery and development program.
Seminars in oncology 1992;19(6):622-38.
1992: Michael R Grever; P Brager; Eric H Kraut; E Metz
A phase II investigation of pentostatin in metastatic malignant melanoma.
Investigational new drugs 1992;10(4):345-6.
1992: John N Weinstein; Kurt W Kohn; Michael R Grever; Vellarkad Viswanadhan; L V Rubinstein; Anne Monks; Dominic A Scudiero; L Welch; A D Koutsoukos; A J Chiausa
Neural computing in cancer drug development: predicting mechanism of action.
Science (New York, N.Y.) 1992;258(5081):447-51.
1992: Donna Ryan; Kenneth J Kopecky; D Head; Michael R Grever; S M Shiaer; D A Lipschitz; HE Hynes; R H Vial; R W Veith; C H Gumbart
Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study.
American journal of clinical oncology 1992;15(1):69-75.
1991: Jean L Grem; S A King; H G Chun; Michael R Grever
Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy.
American journal of hematology 1991;38(3):245-7.
1991: J Schweitzer; F G Handley; J Edwards; W F Harris; Michael R Grever; S A Schepartz; Gordon M Cragg; K Snader; A Bhat
Summary of the workshop on Drug Development, Biological Diversity, and Economic Growth.
Journal of the National Cancer Institute 1991;83(18):1294-8.
1991: B T French; D E Patrick; Michael R Grever; R W Trewyn
Queuine, a tRNA anticodon wobble base, maintains the proliferative and pluripotent potential of HL-60 cells in the presence of the differentiating agent 6-thioguanine.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(2):370-4.
1990: Michael R Grever; J Crowley; S Salmon; R McGee; E H Kraut; S S Buys; S E Rivkin
Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1990;82(22):1778-9.
1990: Pierre L Triozzi; J J Rinehart; L Malspeis; Donn C Young; Michael R Grever
Immunological effects of flavone acetic acid.
Cancer research 1990;50(20):6483-5.
1990: Michael R Grever; J Leiby; Eric H Kraut; E Metz; J Neidhart; S Balcerzak; L Malspeis
A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):39-48.
1990: L Malspeis; Michael R Grever; A E Staubus; D Young
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):18-32.
1990: Eric H Kraut; J C Neff; B A Bouroncle; D Gochnour; Michael R Grever
Immunosuppressive effects of pentostatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(5):848-55.
1990: Bruce D Cheson; Peter A Cassileth; D R Head; Charles Alan Schiffer; J M Bennett; C D Bloomfield; R Brunning; R P Gale; Michael R Grever; M J Keating
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(5):813-9.
1990: E H Kraut; J J Crowley; Michael R Grever; M D Keppen; J D Bonnet; HE Hynes; Sydney E Salmon
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
Investigational new drugs 1990;8(2):199-200.
1990: B T French; D E Patrick; Michael R Grever; R W Trewyn
Differential effect of 6-ethylmercaptopurine on c-myc expression in wild-type and HGPRT-deficient HL-60 cells.
Cancer chemotherapy and pharmacology 1990;27(3):171-7.
1989: Bruce D Cheson; J M Bennett; Kanti Rai; Michael R Grever; N E Kay; M M Oken; Charles Alan Schiffer; M J Keating; D H Boldt; Sanford J. Kempin
Chronic lymphocytic leukemia: recommendations.
Annals of internal medicine 1989;110(8):664-5.
1989: Eric H Kraut; B A Bouroncle; Michael R Grever
Pentostatin in the treatment of advanced hairy cell leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):168-72.
1988: Bruce D Cheson; J M Bennett; Kanti Rai; Michael R Grever; N E Kay; Charles Alan Schiffer; M M Oken; M J Keating; D H Boldt; Sanford J. Kempin
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
American journal of hematology 1988;29(3):152-63.
1988: J M Leiby; Michael R Grever; A E Staubus; J A Neidhart; L Malspeis
Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Journal of the National Cancer Institute 1988;80(6):447-9.
1988: Michael R Grever; K J Kopecky; C A Coltman; J C Files; B R Greenberg; J J Hutton; R Talley; Daniel Von Hoff; S P Balcerzak
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Nouvelle revue française d'hématologie 1988;30(5-6):457-9.
1987: Michael R Grever
Treatment of patients with acute nonlymphocytic leukemia not in remission.
Seminars in oncology 1987;14(4):416-24.
1987: Donna Ryan; Kenneth J Kopecky; D Head; C N Gumbart; Michael R Grever; Chatchada Karanes; J K Weick; C A Coltman
Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(7-8):713-6.
1987: J M Leiby; K M Snider; Eric H Kraut; E N Metz; L Malspeis; Michael R Grever
Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Cancer research 1987;47(10):2719-22.
1987: B A Bouroncle; Michael R Grever; Eric H Kraut
Treatment of hairy cell leukemia: the Ohio State University experience with deoxycoformycin.
Leukemia 1987;1(4):350-4.
1986: Eric H Kraut; B A Bouroncle; Michael R Grever
Low-dose deoxycoformycin in the treatment of hairy cell leukemia.
Blood 1986;68(5):1119-22.
1986: R W Trewyn; Michael R Grever
Urinary nucleosides in leukemia: laboratory and clinical applications.
Critical reviews in clinical laboratory sciences 1986;24(1):71-93.
1985: Michael R Grever; J M Leiby; Eric H Kraut; H E Wilson; J A Neidhart; R L Wall; S P Balcerzak
Low-dose deoxycoformycin in lymphoid malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(9):1196-201.
1985: C Camisa; Michael R Grever; B Bouroncle
Deoxycoformycin: a new chemotherapeutic agent of interest to dermatologists.
Journal of the American Academy of Dermatology 1985;12(6):1108-9.
1984: J A Neidhart; D Derocher; Michael R Grever; Eric H Kraut; L Malspeis
Phase I trial of teroxirone.
Cancer treatment reports 1984;68(9):1115-9.
1983: D A Heldman; Michael R Grever; J S Miser; R W Trewyn
Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia.
Journal of the National Cancer Institute 1983;71(2):269-73.
1983: D A Heldman; Michael R Grever; C E Speicher; R W Trewyn
Urinary excretion of modified nucleosides in chronic myelogenous leukemia.
The Journal of laboratory and clinical medicine 1983;101(5):783-92.
1983: Michael R Grever; Emil Bisaccia; Dwight Scarborough; E N Metz; J A Neidhart
An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
Blood 1983;61(2):279-82.
1983: D A Heldman; Michael R Grever; R W Trewyn
Differential excretion of modified nucleosides in adult acute leukemia.
Blood 1983;61(2):291-6.